Dosis Sola Facit Venenum – The TAB08 (aka TGN1412) Relaunch
It is a while ago (2006) when TeGenero ran its ill-fated Phase 1 study of TGN-1412, a CD28 superagonist slated for studies in diseases like rheumatoid arthritis and B-cell CLL. Unexpectedly, in this FIM study, TGN1412 generated a cytokine release Continue reading Dosis Sola Facit Venenum – The TAB08 (aka TGN1412) Relaunch